OR WAIT null SECS
February 25, 2021
The company will join the network of approved manufacturers of the lipid excipients.
February 24, 2021
Through the acquisition, PharmaLex will expand its capabilities in the biopharma sector while enhancing its global market reach with a new location in Australia.
February 23, 2021
Through the acquisition, Catalent will establish pDNA development and manufacturing services at its Rockville, MD, facility and will gain Delphi’s team of R&D and genetic engineering scientists, technicians, and regulatory specialists.
February 22, 2021
The companies will co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications.
With the acquisition, Eurofins gets Beacon’s G-protein coupled receptor research knowledge and its compound library.
Once the vaccine has been authorized, Sanofi will provide Johnson & Johnson with access to its vaccine manufacturing plant in Marcy l’Etoile, France, to formulate and fill vials of the vaccine, at a rate of 12 million doses per month.
February 18, 2021
The deal expands Wavelength’s drug substance manufacturing footprint and its API CDMO business.
Through the agreement, Catalent will manufacture LUPKYNIS (voclosporin), Aurinia’s drug for the treatment of adult patients with lupus nephritis, at its pharmaceutical softgel center of excellence in St. Petersburg, FL.
The companies have expanded their agreement to include the research and development of new therapies for influenza and other respiratory viruses.
February 17, 2021
The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.